Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SEATTLE, Feb. 22, 2016 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston.
Brad Gray, President and Chief Executive Officer, is scheduled to present on Monday, March 7, 2016 at 1:20pm ET. Interested parties can access the live webcast with accompanying slides from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Investor Contact: Leigh Salvo of Westwicke Partners For NanoString Technologies [email protected] 415-513-1281
